Manila Times Business
Levicept to Present Data Suggesting LEVI-04 May Modify Disease in Osteoarthritis at EULAR 2026
Further clinical efficacy and pharmacology data also to be presented SANDWICH, United Kingdom, June 03, 2026 (GLOBE NEWSWIRE) -- Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class treatment for osteoarthritis (OA), will present key data from its Phase II study of LEVI-04 in patients with pain and disability due to OA of the knee at the European Alliance of Associations for Rheumatology (EULAR) conference being held in London from 3 - 6 June. This will i
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
Bata, Django, De la Cruz lead coaching staff of new billiards NSA
2h ago
Tokenized Cash Management Advisory Group Publishes the Scope of Its Work Program
2h ago
COSMOBEAUTÉ MALAYSIA & BEAUTYEXPO 2026 RETURNS TO KLCC TO DRIVE B2B EXCELLENCE AND NEW BUSINESS FRONTIERS
2h ago
Regent Hong Kong Named Among First-Ever Winners of Condé Nast Traveler's Triple Crown Award
2h ago